论文部分内容阅读
确诊十二指肠溃疡127例,随机分为四组:洛赛克治疗组,每日口服洛赛克20mg,2～4周后溃疡愈合即停药观察;雷尼替丁治疗组,每日2次口服雷尼替T150mg,2～4周后溃疡愈合即停药观察;洛赛克预防组,经济赛克治疗,溃疡愈合后,每周三和周六各服洛赛克20mg,持续一年;雷尼替丁预防组,经雷尼替丁治疗,溃疡愈合后,每晚口服雷尼替丁150mg,持续一年。结果:洛赛克治疗组的半年和一年的溃疡复发率分别为23.3％和33.3％,雷尼替丁治疗组分别为43.3％和73.3％,前者不论半年或一年的复发率均明显低于后者(P<0.02或0.01);洛赛克预防组半年和一年的复发率分别为5.8％和8.8％,雷尼替丁预防组分别为24.2％和30.3％,洛赛克预防效果远比雷尼替丁为优。
127 cases of duodenal ulcer diagnosed were randomly divided into four groups: Losec treatment group, daily oral administration of Losec 20mg, 2 to 4 weeks after the ulcer healing that observed withdrawal; ranitidine treatment group, daily 2 oral ranitidine T150mg, 2 to 4 weeks after the withdrawal of ulcer healing observation; Losec prevention group, the economy of Sik, ulcer healing, every Wednesday and Saturday, each serving of Losec 20mg, for a year ; Ranitidine prevention group, ranitidine treatment, ulcer healing, oral administration of ranitidine 150mg per night for one year. Results: The half-year and one-year ulcer recurrence rates were 23.3% and 33.3% in the Losec group and 43.3% and 73.3% in the ranitidine group, respectively. The former had a significantly lower relapse rate regardless of half year or one year In the latter (P <0.02 or 0.01), the half-year and one-year recurrence rates were 5.8% and 8.8% for the Losec group and 24.2% and 30.3% for the ranitidine group, respectively Far better than ranitidine.